Oh DY - Search Results

1

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.

Melisi D, Oh DY, Hollebecque A, Calvo E, Varghese A, Borazanci E, Macarulla T, Merz V, Zecchetto C, Zhao Y, Gueorguieva I, Man M, Gandhi L, Estrem ST, Benhadji KA, Lanasa MC, Avsar E, Guba SC, Garcia-Carbonero R. Melisi D, et al. Among authors: oh dy. J Immunother Cancer. 2021 Mar;9(3):e002068. doi: 10.1136/jitc-2020-002068. J Immunother Cancer. 2021. PMID: 33688022 Free PMC article. Clinical Trial.

2

Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.

Lee JJ, Kim TM, Yu SJ, Kim DW, Joh YH, Oh DY, Kwon JH, Kim TY, Heo DS, Bang YJ, Kim NK. Lee JJ, et al. Among authors: oh dy. Jpn J Clin Oncol. 2004 Jul;34(7):400-4. doi: 10.1093/jjco/hyh068. Jpn J Clin Oncol. 2004. PMID: 15342667 Clinical Trial.

3

Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.

Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY. Han SW, et al. Among authors: oh dy. Cancer Sci. 2010 Mar;101(3):793-9. doi: 10.1111/j.1349-7006.2009.01447.x. Epub 2009 Nov 23. Cancer Sci. 2010. PMID: 20047592 Free article. Clinical Trial.

4

Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.

Kim JW, Lee JO, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Kim JW, et al. Among authors: oh dy. Am J Clin Oncol. 2011 Apr;34(2):125-9. doi: 10.1097/COC.0b013e3181d31ed2. Am J Clin Oncol. 2011. PMID: 20308869

5

Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy.

Yhim HY, Han SW, Oh DY, Han W, Im SA, Kim TY, Kim YT, Noh DY, Chie EK, Ha SW, Park IA, Bang YJ. Yhim HY, et al. Among authors: oh dy. Cancer. 2010 Jun 15;116(12):2890-901. doi: 10.1002/cncr.25054. Cancer. 2010. PMID: 20564396 Free article.

6

Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.

Nam HJ, Ching KA, Kan J, Kim HP, Han SW, Im SA, Kim TY, Christensen JG, Oh DY, Bang YJ. Nam HJ, et al. Among authors: oh dy. Mol Cancer Ther. 2012 Feb;11(2):439-51. doi: 10.1158/1535-7163.MCT-11-0494. Epub 2011 Dec 1. Mol Cancer Ther. 2012. PMID: 22135232

7

Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.

Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, Lee HJ, Lee KW, Bang YJ. Oh DY, et al. Cancer. 2012 Dec 15;118(24):6162-70. doi: 10.1002/cncr.27675. Epub 2012 Jun 26. Cancer. 2012. PMID: 22736481 Free article. Clinical Trial.

8

Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.

Han SW, Cha Y, Paquet A, Huang W, Weidler J, Lie Y, Sherwood T, Bates M, Haddad M, Park IH, Oh DY, Lee KS, Im SA, Bang YJ, Ro J, Kim TY. Han SW, et al. Among authors: oh dy. PLoS One. 2012;7(7):e39943. doi: 10.1371/journal.pone.0039943. Epub 2012 Jul 27. PLoS One. 2012. PMID: 22848366 Free PMC article. Clinical Trial.

9

Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells.

Kim HJ, Kim HP, Yoon YK, Kim MS, Lee GS, Han SW, Im SA, Kim TY, Oh DY, Bang YJ. Kim HJ, et al. Among authors: oh dy. Anticancer Drugs. 2012 Mar;23(3):288-97. doi: 10.1097/CAD.0b013e32834e7d9b. Anticancer Drugs. 2012. PMID: 23422737

10

Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.

Kim JW, Kim JH, Im SA, Lee KH, Kim JS, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA. Kim JW, et al. Among authors: oh dy. Cancer Chemother Pharmacol. 2013 Nov;72(5):1023-9. doi: 10.1007/s00280-013-2268-9. Epub 2013 Sep 15. Cancer Chemother Pharmacol. 2013. PMID: 24036907

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

747 results

Search Page